You are viewing the site in preview mode

Skip to main content

Table 3 Submission and consideration of PROs as part of the early benefit assessment process of rare diseases

From: Patient-reported data informing early benefit assessment of rare diseases in Germany: A systematic review

CategoryNumber of PRO data sets (n)Percentage of events in relation to overall number of processes (%)
Industry – type of PRO data submitted (module 4)
 Clinical PROs4151%
 HRQoL6175%
 Preferences22%
 Satisfaction11%
Industry - extent of PRO data submitted (module 4)
 No PRO data submitted1316%
 Data on one PRO category3543%
 Data on two PRO categories3138%
 Data on three PRO categories22%
Early benefit assessment – type of PRO data considered in synopsis
 Clinical PRO3948%
 HRQoL5872%
 Preferences00%
 Satisfaction00%
Early benefit assessment – extent of PRO data submitted
 No PRO data considered4353%
 One PRO category6378%
 Two PRO categories5467%
 Three PRO categories22%
GBA decision – extent of PRO data considered in the decision
 No PRO data considered3138%
 One PRO category2531%
 Two PRO categories2531%
 Three PRO categories00%
GBA decision – type of PRO data considered in the decision
 Clinical PROs3948%
 HRQoL5973%
 Preferences00%
 Satisfaction00%
Comparison between data submitted and data considered by the GBA
 Identical number of PRO categoriesa4250%
 Diverging number of PRO categoriesa2940%
 Clinical PROs - not considered by GBA821%
 Clinical PROs - added by GBA615%
 HRQoL - not considered by GBA1931%
 HRQoL – added in GBA decision23%
 Preferences – not considered by GBA2100%
 Satisfaction – not considered by GBA1100%
  1. GBA German Federal Joint Committee, HRQoL Health Related Quality of Life, PRO Patient-reported Outcomes. aThe number does not add up to n = 81 (all regarded processes) as some manufacturers did not provide PRO data